The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006

Antiviral Research

Volumn 75, Issue 2, 2007, Pages 173-176

  Barr, I G ^a,b   Hurt, A C ^a,b   Deed, N ^a   Iannello, P ^a   Tomasov, C ^a   Komadina, N ^a  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b UNIVERSITY OF BALLARAT   (Australia)

Author keywords

Amantadine; Australia; Matrix gene; Resistance; Rimantadine; South East Asia

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; RIMANTADINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CHILD; CONTROLLED STUDY; GENOTYPE; HUMAN; INFANT; INFLUENZA VIRUS A; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TYPING; WORLD HEALTH ORGANIZATION;

ADAMANTANE; ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; ASIA, SOUTHEASTERN; AUSTRALIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FAR EAST; GENOTYPE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MIDDLE AGED; PACIFIC ISLANDS; PREVALENCE; RIMANTADINE; SOUTH AFRICA;

INFLUENZA A VIRUS;

EID: 34247626313     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.01.006     Document Type: Article

References (18)

1. Aoki F.Y. Amantadine and rimantadine. In: Nicholson K.G., Webster R.G., and Hay A.J. (Eds). Textbook of Influenza (1998), Blackwell Science, Oxford 457-476
2. Astrahan P., Kass I., Cooper M.A., and Arkin I.T. A novel method of resistance for influenza against a channel-blocking antiviral drug. Proteins 55 (2004) 251-257
3. Barr I.G., Komadina N., Hurt A.C., Shaw R., Durrant C., Iannello P., Tomasov C., Sjogren H., and Hampson A. Reassortments in recent human influenza A and B isolates from South East Asia and Oceania. Virus Res. 98 (2003) 35-44
4. Barr I.G., Hurt A.C., Iannello P., Tomasov C., Deed N., and Komadina N. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Res. 73 (2007) 112-117
5. Belshe R.B., Burk B., Newman F., Cerruti R.L., and Sim L.S. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J. Infect. Dis. 159 (1989) 430-435
6. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.T., Davis X.M., Poyinelli L., Cox N.J., and Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005) 1175-1181
7. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated during the 2005-2006 influenza season in the United States. JAMA 295 (2006) 891-894
8. Centre for Disease Control (CDC). Concepts and procedures for laboratory based influenza surveillance. U.S. Department of Health, Public Health Service, Atlanta, Georgia, 1982.
9. Centre for Disease Control and Prevention (CDC), 2006. High levels of adamantane resistance among influenza A(H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-2006 influenza season. MMWR Morb Mortal Wkly Rep 55, pp. 44-46.
10. Cheung C.L., Rayner J.M., Gavin J.D., Wang P., Naipospos T.S.P., Zhang J., Yuen K.Y., Webster R.G., Peiris M.K., Guan Y., and Chen H. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193 (2006) 1626-1629
11. Gubareva L.V., Kaiser L., and Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet 355 (2000) 827-835
12. Hay A.J., Wolestenholm A.J., Skehel J.J., and Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO 4 (1985) 3021-3024
13. Hay A.J., Zambon M.C., and Woltstenholme A.J. Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrobiol. Chemother. 18 (1986) 19-29
14. Hay A.J. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Virology 3 (1992) 21-30
15. Hurt A.C., Selleck P., Komadina K., Shaw R., and Barr I.G. Susceptibility of highly pathogenic H5N1 avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73 (2007) 228-231
16. Pinto L.H., Holsinger L.J., and Lamb L.A. Influenza virus M2 protein has ion channel activity. Cell 69 (1992) 517-528
17. Saito, R., Sakai, T., Sato., Sano, Y., Oshitani, H., Sato, M., Suzuki, H., 2003. Frequency of adamantane-resistant influenza A viruses during two seasons featuring co-circulation of H1N1 and H3N2. J. Clin. Microbiol. 41, 2164-2165.
18. Shiraishi K., Mitamura K., Sakai-Tagawa Y., Goto H., Sugaya N., and Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J. Infect. Dis. 188 (2003) 57-61